Stem cell transplant aims to halt vision loss in dry AMD

NCT ID NCT02286089

First seen Nov 05, 2025 · Last updated Jun 12, 2026 · Updated 32 times

Summary

This study tests a new treatment called OpRegen, made from stem cells, for people with advanced dry age-related macular degeneration (AMD). The cells are placed under the retina to replace damaged cells and slow disease progression. The trial involves 24 adults aged 50 and older with severe vision loss. The main goal is to check safety, but researchers will also see if the treatment helps preserve or improve eyesight.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cincinnati Eye Institute

    Cincinnati, Ohio, 45242, United States

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • Kaplan Medical Center

    Rehovot, 76100, Israel

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania, 19107, United States

  • Rabin Medical Center

    Petah Tikva, 4941492, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 6423906, Israel

  • West Coast Retina Medical Group

    San Francisco, California, 94109, United States

Conditions

Explore the condition pages connected to this study.